An interventional study of Type 1 myotonic dystrophy in Myotonic Dystrophy 1, sponsored by Centre Hospitalier Universitaire de Nice. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-21.
Sponsored by Centre Hospitalier Universitaire de Nice · Not applicable, Interventional, and Diagnostic
Type 1 myotonic dystrophy (MD1) is a genetic and hereditary disease that primarily affects muscle tissue, resulting in myotonia (difficulty relaxing after contraction) and atrophy (progressive muscle weakening with decreased muscle volume). It also affects eyes, heart, endocrine system, gastrointestinal system and central nervous system. Specific cognitive abilities are impaired in patients with MD1 such as attention, visio-spatial or visio-building abilities as well as executive dysfunctions.
Currently, the cognitive assessment of MD1 patients is based on classical neuropsychological tests, which are time-consuming and require a MD1 expert neuropsychologist. Moreover, it is usually very difficult for MD1 patients to accept performing these tests, and when they agree to perform them, they usually give up before the end. This finding is more frequent in MD1 patients with high level of cognitive impairment.
In order to overcome these difficulties in assessing cognitive functions of MD1 patients, the investigators decided to use innovative tools such as virtual reality, which allow individuals to experience a sensory-motor and cognitive experience in a digitally world through a helmet, glasses and joysticks.
The start-up My Cyber Royaume from Lille, in collaboration with the reference center of neuromuscular diseases from Nice coordinated by Pr Sacconi, have developed a software "Good Diag NMD" which uses virtual reality to assess cognitive disorders, more specifically executive functions in patients with type 1 myotonic dystrophy.
125 studies on the registry are indexed under Myotonic Dystrophy; 51 are open to participants now.
Browse Myotonic Dystrophy studies →Centre Hospitalier Universitaire de Nice is the lead sponsor of 709 studies on the registry; 176 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Type 1 myotonic dystrophy patients doing classical neuropsychological test and on "Good Diag NMD" software
Diagnostic Test: Type 1 myotonic dystrophy
To compare classical neuropsychological test and on "Good Diag NMD" software in Type 1 myotonic dystrophy patients
Evaluate the feasibility of the use "Good Diag NMD" software in the evaluation of cognitive executive dysfunctions in patients with dystrophy myotonia 1
The feasibility "Good Diag NMD" software in patient with type 1 myotonic dystrophy (DM1) will be determined as the rate of patients having completed the Good Diag NMD session in full. Satisfactory feasibility is considered if this rate of patients is greater or equal to 50%.
Time frame: 0 months
Establish a possible relationship between the genotype of DM1 patients and the scores obtained during "Good Diag NMD" session
Genotype of DM1 patients will be determined by molecular biology technique, ie the size of GTC triplet expansion will indicate the of severity of the genetic abnormality . Then, we will analyse a possible correlation of the genotype with the scores obtained during "Good Diag NMD" session.
Time frame: 0 months
To compare the satisfaction score of type 1 myotonic dystrophy patients between classic neuropsychological tests and the Good Diag NMD session
The satisfaction will be measured with a satisfaction questionnaire called "Assessment questionnaire" (value between 0 to 50)
Time frame: 0 months
Compare the scores of "Good Diag NMD" session (scores of perseveration, inhibition and flexibility) with the scores of the classical neuropsychological tests
The following correlations will be examined studied: * The level of correlation between perseveration score (0-149) and Frontal Efficiency Rapid Battery (BREF) score (0-18) * The perseveration score (0-149) and Short Cognitive Battery (B2C) score * The inhibition score (0-77) and interference score (score I) from Stroop test (-30 and +30) * flexibility score (0-119) and completion time of Trail Making Test (TMT) B
Time frame: 0 months
Establish a possible correlation between the severity of the disease, the severity of muscular impairment and the scores of Good Diag NMD session
Time frame: 0 months
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is withdrawn, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire de Nice